Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Sarcoma 1Head & Neck 1

Conditions

Sarcoma 7Nasopharyngeal Carcinoma 2Liposarcoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 5Fluorouracil 4pembrolizumab 3fludarabine 3Gemcitabine 3Docetaxel 3Cisplatin 3belinostat 2Quality of Life 2Psychiatric Rehabilitation 2Oxaliplatin 2Observation 2Leucovorin 2Irinotecan 2Filgrastim 2Erlotinib Hydrochloride 2Drug Therapy 2Cetuximab 2Carboplatin 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2umbralisib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1seribantumab 1rucaparib 1resiquimod 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × toripalimab × Sarcoma × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡